## Erratum: New Players in TLR-Mediated Innate Immunicty: P13K and Small Rho GTPases

## Monica Ruse <br> Ulla G. Knaus

The correct Table 1 for this article, which appeared in Immunologic Research, volume 34, no. 1, pp. 33-48, is printed below.

| TLR stimulus | Cell type | PI3K in | $r$ PI3K effect | PI3K potential mechanism of action | References |
| :---: | :---: | :---: | :---: | :---: | :---: |
| Anti-inflammatory |  |  |  |  |  |
| Poly(I:C): *** *, LPS: * | Human monocytederived DCs. | $\begin{aligned} & \text { LY: } \star \star \\ & \text { Wo: } \end{aligned}$ | IFN- $\beta \downarrow$ | Involvement in TRIF-dependent NF-KB activity | (33) |
| LPS: *** | Human monocytic cells | LY: • Wo: | TNF $\alpha$ and TF $\downarrow$ | MAPK pathways, NF-кB activity | (36) |
| LPS: ** | Murine macrophage Raw 264.7 | LY: •• Wo: | iNOS and NO $\downarrow$ | NF-кB activation and iNOS transcription | (30) |
| LPS: * | Murine peritoneal macrophages | Wo: * | iNOS and TNF $\alpha \downarrow$ | Not determined | (31) |
| LPS: * | Human alveolar macrophages | LY: * | COX2 $\downarrow$ | Destabilization of COX2 mRNA via p38 | (29) |
| $\begin{aligned} & \hline \text { LPS: **, PGN: *** } \\ & \text { C }_{\mathrm{p}} \text { G ODN: } \bullet * \\ & \hline \end{aligned}$ | BM- DCs or splenic DCs from PI3K | Wo: * | IL-12 $\downarrow$ | Inhibition of p38 activity | (39) |
| Pro-inflammatory |  |  |  |  |  |
| Poly(I:C): **** | HEK293 cells stably transfected with TLR3 | LY: ** | p56 protein $\uparrow$ | Phosphorylation and activation of IRF-3 | (53) |
| HKSA | THP1 human monocytes | Wo: * LY: * | NF-кB- dependent gene transcription $\uparrow$ | NF-kB transactivation | (27) |
| BCG wcl: ** | Raw 264.7 | LY: ** | MIP2 and NO $\uparrow$ | p65 association with p300/CBP coactivator | (50) |
| LPS: ** | Raw 264.7 | LY: * * * <br> Wo: | $\mathrm{IL}-1 \beta \uparrow$ | N-FkB transactivation | (28) |
| LPS: ** | Raw 264.7 | LY: ** | IL-1 $\beta$ 个 | JNK activation | (26) |
| $\begin{aligned} & \text { LPS: }{ }^{* *} \\ & \text { PGN: } * * * \text { PamCSK4: } * * * * \end{aligned}$ | Bone marrow-derived mouse neutrophils | Wo: | TNF $\alpha$ and MIP2 $\uparrow$ | p38 and ERK1/2 activation | (45) |
| $\begin{aligned} & \text { LPS: *, PGN: ** } \\ & \text { PamCSK4: **, MALP2: * } \end{aligned}$ | Human neutrophils | Wo: ** | Pro-survival | Mcl-1 and A1 $\uparrow$ | (47) |
| LPS: ** | Human neutrophils | LY: * | Pro-survival | Not determined | (48) |
| CpG ODN: * | Mouse splenic DCs | LY: ** | Pro-survival | cIAPs $\uparrow$ | (49) |

[^0]
[^0]:    .
    The following concentrations should serve as guidelines: $10 \mathrm{ng} / \mathrm{ml} \leq * \leq 100 \mathrm{ng} / \mathrm{ml} \leq * * \leq 1 \mu \mathrm{~g} / \mathrm{ml} \leq * * * \leq 10 \mu \mathrm{~g} / \mathrm{ml} \leq * * * * \leq 100 \mu \mathrm{~g} / \mathrm{ml}$
    $10 \mathrm{nM} \leq \bullet \leq 100 \mathrm{nM} \leq \bullet \bullet 10 \mu \mathrm{M} \leq \bullet \bullet \leq 50 \mu \mathrm{M}$

